Adagene (ADAG) Competitors $1.91 -0.04 (-2.05%) Closing price 10/13/2025 03:59 PM EasternExtended Trading$1.95 +0.04 (+2.09%) As of 10/13/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. REPL, DMAC, BNTC, LXEO, IMAB, ALT, DBVT, EDIT, ALTS, and ANNXShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Replimune Group (REPL), DiaMedica Therapeutics (DMAC), Benitec Biopharma (BNTC), Lexeo Therapeutics (LXEO), I-Mab (IMAB), Altimmune (ALT), DBV Technologies (DBVT), Editas Medicine (EDIT), ALT5 Sigma (ALTS), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Replimune Group DiaMedica Therapeutics Benitec Biopharma Lexeo Therapeutics I-Mab Altimmune DBV Technologies Editas Medicine ALT5 Sigma Annexon Replimune Group (NASDAQ:REPL) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Does the media refer more to REPL or ADAG? In the previous week, Adagene had 1 more articles in the media than Replimune Group. MarketBeat recorded 3 mentions for Adagene and 2 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.95 beat Adagene's score of 0.83 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in REPL or ADAG? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, REPL or ADAG? Replimune Group has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Which has better valuation & earnings, REPL or ADAG? Adagene has higher revenue and earnings than Replimune Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.41Adagene$100K900.18-$33.42MN/AN/A Do analysts rate REPL or ADAG? Replimune Group presently has a consensus price target of $6.50, indicating a potential upside of 42.54%. Adagene has a consensus price target of $7.00, indicating a potential upside of 266.49%. Given Adagene's stronger consensus rating and higher probable upside, analysts clearly believe Adagene is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 3 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.91Adagene 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Is REPL or ADAG more profitable? Adagene's return on equity of 0.00% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% Adagene N/A N/A N/A SummaryAdagene beats Replimune Group on 10 of the 12 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.91M$3.36B$6.05B$10.30BDividend YieldN/A2.31%5.73%4.82%P/E RatioN/A22.0885.3127.10Price / Sales900.18478.69601.46133.24Price / CashN/A44.9825.7730.18Price / Book1.6810.3812.676.69Net Income-$33.42M-$52.47M$3.32B$276.55M7 Day Performance-4.02%0.18%-0.06%-0.40%1 Month Performance-14.73%13.95%8.73%6.53%1 Year Performance-13.57%20.83%78.85%41.04% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.4836 of 5 stars$1.91-2.1%$7.00+266.5%-9.9%$91.91M$100K0.00260REPLReplimune Group4.6768 of 5 stars$4.68-1.1%$6.50+38.9%-60.3%$369.21MN/A-1.44210Positive NewsDMACDiaMedica Therapeutics1.9108 of 5 stars$6.93-2.0%$12.33+78.0%+66.1%$365.44MN/A-10.0420BNTCBenitec Biopharma1.9683 of 5 stars$13.66-1.3%$24.80+81.6%+38.1%$363.30MN/A-9.2920LXEOLexeo Therapeutics2.7526 of 5 stars$6.47-2.3%$15.33+137.0%+0.1%$357.49MN/A-1.9858IMABI-Mab2.73 of 5 stars$4.35+0.7%$7.33+68.6%+355.9%$355.22MN/A0.00380Analyst UpgradeGap UpALTAltimmune2.9713 of 5 stars$4.01+2.6%$17.40+333.9%-36.5%$353.91M$20K-3.4050Analyst ForecastDBVTDBV Technologies1.3241 of 5 stars$13.29+3.0%$14.75+11.0%+373.5%$353.40MN/A-2.7980High Trading VolumeEDITEditas Medicine4.2632 of 5 stars$3.80-3.1%$5.10+34.2%+11.6%$352.49M$38.90M-1.33230ALTSALT5 Sigma0.4935 of 5 stars$2.95+2.8%N/A+34.3%$351.89M$12.53M0.00170Positive NewsGap DownANNXAnnexon2.4709 of 5 stars$3.18-0.3%$12.50+293.1%-59.2%$349.44MN/A-2.4760Positive News Related Companies and Tools Related Companies REPL Competitors DMAC Competitors BNTC Competitors LXEO Competitors IMAB Competitors ALT Competitors DBVT Competitors EDIT Competitors ALTS Competitors ANNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredIs your money positioned for what’s coming?The 7 red flags Wall Street won’t talk aboutAmerican Alternative | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
